Overview of Q3 2025 Financial Results
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) unveiled its financial results for the third quarter of 2025, painting a promising picture for the clinical-stage biopharmaceutical company. Galmed focuses on innovative treatments targeting liver, cardiometabolic, and gastrointestinal oncology indications.
Financial Summary
As of September 30, 2025, Galmed reported a robust total of approximately $19.2 million in cash and cash equivalents. This marks a notable increase compared to $15.4 million from the end of the previous fiscal year. The company’s financial health reflects its efforts to manage resources effectively and sustain growth.
Net Loss Report
During the third quarter, Galmed reported a net loss of approximately $2.0 million, or $0.33 per share. This loss shows an increase from the previous year’s loss of $1.9 million, or $2.31 per share, as of the same period. The shift largely stems from enhanced investments in research and development combined with the escalating costs of clinical trials.
Research and Development Expenses
Research and development expenses for Q3 2025 totaled around $1.1 million, increasing from the approximately $0.7 million spent in Q3 2024. This rise indicates Galmed’s commitment to advancing its innovative treatment modalities, particularly in clinical and pre-clinical trials.
Administrative Costs Overview
General and administrative expenses decreased to approximately $1.0 million for the current quarter, compared to $1.3 million in the same quarter of last year. This decline is primarily due to a reduction in salaries and overall benefit expenses.
Recent Business Developments
Collaborative Research Success
On November 17, 2025, Galmed revealed promising top-line results from a collaborative study with Virginia Commonwealth University (VCU). This research evaluated the effectiveness of Aramchol, combined with Stivarga and Metformin, in overcoming drug resistance in gastrointestinal cancer treatments, showcasing notable improvements in tumor cell lethality both in vitro and in vivo.
Advancements with AM-001 Study
Just a day later, Galmed announced further fruitful results from its AM-001 study, focusing on the Phase 1 bioavailability trial of Aramchol Meglumine. These developments are pivotal for the company, signaling progress in their therapeutic advancements.
Strategic Financial Movements
In connection with its growth strategy, Galmed secured approximately $9.3 million in funding throughout 2025 through equity lines and various ATM facilities. These funds are crucial as Galmed continues to invest in its pipeline and expand into new potential markets.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is dedicated to the development of Aramchol, primarily targeting treatments for liver diseases. The firm is also diversifying its product pipeline with a specific focus on cardiometabolic conditions and other innovative candidates that fit their core capabilities in drug development. The company actively works to position itself at the forefront of advancing healthcare solutions.
Frequently Asked Questions
What are Galmed Pharmaceuticals' recent earnings?
In Q3 2025, Galmed Pharmaceuticals reported a net loss of approximately $2.0 million.
How much funding did Galmed secure in 2025?
Galmed raised approximately $9.3 million through equity lines and ATM facilities throughout 2025.
What are the company's main research focuses?
Galmed is focused on innovative treatments for liver diseases, cardiometabolic conditions, and gastrointestinal oncology treatments.
How has the financial landscape shifted for Galmed?
Galmed has increased its cash reserves, reporting $19.2 million as of September 30, 2025, compared to the previous year's figure at $15.4 million.
What recent partnerships has Galmed engaged in?
Galmed recently collaborated with Virginia Commonwealth University to evaluate the efficacy of Aramchol in gastrointestinal cancers.
